Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

Beyond the encouraging results and broad clinical applicability of immune checkpoint (ICP) inhibitors in cancer therapy, ICP-based immunotherapies in the context of autoimmune disease, particularly multiple sclerosis (MS), have garnered considerable attention and hold great potential for developing...

Descripción completa

Detalles Bibliográficos
Autores principales: Daei Sorkhabi, Amin, Komijani, Erfan, Sarkesh, Aila, Ghaderi Shadbad, Pedram, Aghebati-Maleki, Ali, Aghebati-Maleki, Leili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634124/
https://www.ncbi.nlm.nih.gov/pubmed/37946301
http://dx.doi.org/10.1186/s12964-023-01289-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634124/
https://www.ncbi.nlm.nih.gov/pubmed/37946301
http://dx.doi.org/10.1186/s12964-023-01289-9

Ejemplares similares